ICER Outlines Planned Review of High Cholesterol Treatments
The Institute for Clinical and Economic Review (ICER) in a recently-released document outlines its planned review of high cholesterol treatments. [...]
Panel Discusses Provider Prospective on Value-Based Care for mBC
A recent panel discussion on AJMC's Peer Exchange discusses how providers identify value-based care opportunities for metastatic breast cancer. The [...]
Evidation Looks to Bolster Platform to Include Virtual Treatment
After generating $45 million in investments, Evidation is looking to expand its virtual research platform to include digital interventions and [...]
Gilead CEO: Remdesivir Priced ‘Significantly’ Below Value to Society
Gilead CEO Daniel O'Day told STAT he's confident in the company's pricing decision for the COVID-19 drug remdesivir. "We spent [...]
ICER President: Remdesivir Price was ‘Responsible’ Decisions
The Institute for Clinical and Economic Review's president, Steven Pearson, says Gilead's decision to price its COVID-19 treatment remdesivir at [...]
Oncologists Grapple with Supply Shortages Amid Pandemic, Survey Finds
A new survey found that one of oncologists' biggest concerns amid the COVID-19 pandemic is supply shortages, Specialty Pharmacy Continuum [...]
Proposed Medicaid Changes Aim to Foster Innovative Contracts
The Centers for Medicare and Medicaid Services (CMS) is hoping to encourage greater use of innovative contracting models in a [...]
Cytel Outlines Use of Bayesian Methodologies
A new white paper from Cytel outlines how its statisticians have used Bayesian methodologies in the search for effective COVID-19 [...]
ISPOR Offers Short Courses on Medical Devices, Payment Models
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is offering short courses on medical devices and different payment models [...]
NPC: ‘Ready, aim, fire’ Mentality Detrimental in Health Care
Having a "ready, aim, fire" mentality can prove harmful when sharing health care information, the National Pharmaceutical Council (NPC) writes [...]
Legislation Aims to Prevent Pharma From Price-gouging During Pandemic
Two new bipartisan bills introduced by House Democrats aim to prevent the pharmaceutical industry from engaging in price-gouging on COVID-19 [...]
ISPOR-FDA Summit Transitions to Virtual Event
The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) announced that the joint ISPOR-FDA Summit 2020, set for Sept. 29, [...]
Cytel Offers On-Demand Access to Webinar on Synethic, External Control Arms
A new on-demand webinar from Cytel offers insights into synthetic and external control arms in clinical trials. The webinar features [...]
Kreis: Challenging Price of Costly CF Drug Not ‘Discrimination’
Maurice Kreis, head of the New Hampshire Office of the Consumer Advocate, says challenging the price of Vertex Pharmaceuticals' cystic [...]
ICER to Review Most Significant Drug Price Hikes
The Institute for Clinical and Economic Review (ICER) is set to review whether the most significant drug price increases are [...]
Analysis Finds Clinical Trial Costs are Actually Modest
A new analysis published in BMJ Open suggests that clinical trial costs for new drugs are generally modest, according to [...]
New Definition of HTA
In a letter to the editor published in Value in Health, Brian O'Rourke, Wija Oortwijn and Tara Schuller offer a [...]
Report: EMA Considers Big Data Network ‘Priority’
The European Medicines Agency (EMA) says the development of a big data network is a "priority" project, according to a [...]
ISPOR Europe 2020 Deadline for Abstract Submissions Nears
The abstract submission deadline for ISPOR's upcoming European meeting is July 8. ISPOR 2020 Europe is set to kick off [...]
Researchers Support Targeted Population Health Interventions to Boost COVID-19 Outcomes
Health care systems should target population health interventions to patients with existing chronic diseases to bolster COVID-19 outcomes, researchers in [...]
Where Epidemiologists are Leaning on Kids Returning to School
A recent New York Times Upshot article offers comments from 133 epidemiologists on the matter of children returning to school [...]
Article: U.S. Should Scrap Specialty Drug Label
The U.S. should abandon the specialty-drug label for high-cost drugs and follow suit with other countries that categorize drugs by [...]
ICER to CF Community: ‘We Support Actions to Receive Fair Prices’
The Institute for Clinical and Economic Review (ICER) in a letter to the cystic fibrosis community says it supports fair [...]
How Can Pharma Best Interact with ICER?
A new report from FirstWord looks at how pharma can best engage with the Institute for Clinical and Economic Review [...]
Using AI, NLP and Data Visualization with RWE to Generate Insights into Care Gaps: Retrospective Cohort Analysis of Fracture Risk in Patients with Osteopenia and Osteoporosis
Sponsored by Veradigm Real world data (RWD) are being used by an increasingly diverse group of stakeholders. As an example, [...]